CDTX — Cidara Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $53.87m
- $25.61m
- $63.91m
- 32
- 33
- 72
- 42
Annual cashflow statement for Cidara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.1 | -72.1 | -42.5 | -29.8 | -22.9 |
| Depreciation | |||||
| Non-Cash Items | 4.75 | 4.05 | 2.61 | 4.62 | 4.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.49 | 13.4 | 14.4 | -3.43 | -3.92 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -28.5 | -54.4 | -25.2 | -28.5 | -22.4 |
| Capital Expenditures | -0.035 | -0.186 | -0.041 | -0.118 | -0.505 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.035 | -0.186 | -0.041 | -0.118 | -0.505 |
| Financing Cash Flow Items | -0.031 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.3 | 37.3 | 44.6 | -0.951 | 26 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -14.3 | -17.3 | 19.3 | -29.5 | 3.05 |